Scott N. Cullison
Corporate Officer/Principal en XENETIC BIOSCIENCES, INC. .
Cargos activos de Scott N. Cullison
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
XENETIC BIOSCIENCES, INC. | Corporate Officer/Principal | - | - |
Historial de carrera de Scott N. Cullison
Antiguos cargos conocidos de Scott N. Cullison.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2015 | 01/11/2018 |
PELOTON THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Corporate Officer/Principal | 26/10/2010 | - |
Formación de Scott N. Cullison.
Wake Forest University | Masters Business Admin |
University of Arizona | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
XENETIC BIOSCIENCES, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Scott N. Cullison
- Experiencia